Adjuvanted recombinant hemagglutinin H7 vaccine to highly pathogenic influenza A(H7N9) elicits high and sustained antibody responses in healthy adults (original) (raw)
Highly pathogenic avian influenza A/Guangdong/17SF003/2016 is immunogenic and induces cross-protection against antigenically divergent H7N9 viruses
Ivan Kosik
npj Vaccines
View PDFchevron_right
An Adjuvanted, Low‐Dose, Pandemic Influenza A (H5N1) Vaccine Candidate Is Safe, Immunogenic, and Induces Cross‐Reactive Immune Responses in Healthy Adults
Isabel Leroux-roels, Karel Hoppenbrouwers
The Journal of Infectious Diseases, 2008
View PDFchevron_right
Safety and Cross‐Reactive Immunogenicity of Candidate AS03‐Adjuvanted Prepandemic H5N1 Influenza Vaccines: A Randomized Controlled Phase 1/2 Trial in Adults
Casey Johnson
The Journal of Infectious Diseases, 2010
View PDFchevron_right
An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans
Ariana Hirsh
Clinical and vaccine immunology : CVI, 2014
View PDFchevron_right
Experience with the clinical development of influenza vaccines for potential pandemics
Maria Zambon
Medical Microbiology and Immunology, 2002
View PDFchevron_right
Protection of Mice against Lethal Infection with Highly Pathogenic H7N7 Influenza A Virus by Using a Recombinant Low-Pathogenicity Vaccine Strain
Walter Beyer
Journal of Virology, 2005
View PDFchevron_right
Immunogenicity and tolerability of an AS03A-adjuvanted prepandemic influenza vaccine: A phase III study in a large population of Asian adults
Prasert Thongcharoen, Yee-leong Teoh
Vaccine, 2009
View PDFchevron_right
Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant
David Gordon
Vaccine, 2012
View PDFchevron_right
Analyses of Safety Profile and Homologous Antibody Responses to a Mammalian Cell-Based, MF59-Adjuvanted, A/H5N1, Pandemic Influenza Vaccine across Four Phase II/III Clinical Trials in Healthy Children, Adults, and Older Adults
Esther van Twuijver
Vaccines
View PDFchevron_right
“Trivalent influenza vaccination of healthy adults 3 years after the onset of swine-origin H1N1 pandemic: restricted immunogenicity of the new A/H1N1v constituent?”
Sabine Wicker
Medical Microbiology and Immunology, 2013
View PDFchevron_right
Assessment of Human Immune Responses to H7 Avian Influenza Virus of Pandemic Potential: Results from a Placebo-Controlled, Randomized Double-Blind Phase I Study of Live Attenuated H7N3 Influenza Vaccine
Yulia Desheva
PloS one, 2014
View PDFchevron_right
Antibody response against heterogeneous circulating influenza virus strains elicited by MF59- and non-adjuvanted vaccines during seasons with good or partial matching between vaccine strain and clinical isolates
P. Durando
Vaccine, 2010
View PDFchevron_right
Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects
Esther van Twuijver
Vaccines, 2022
View PDFchevron_right
Pandemic influenza virus vaccines boost hemagglutinin stalk-specific antibody responses in primed adult and pediatric cohorts
Weina Sun
npj Vaccines
View PDFchevron_right
Comparison of A(H3N2) Neutralizing Antibody Responses Elicited by 2018–2019 Season Quadrivalent Influenza Vaccines Derived from Eggs, Cells, and Recombinant Hemagglutinin
Maryna Eichelberger
Clinical Infectious Diseases, 2020
View PDFchevron_right
Evaluating the Immune Response of Recombinant H1N1 Hemagglutinin with MF59 Adjuvant in Animal Model as a Novel Alternative to the Influenza Vaccine
Mehdi Mahdavi
Iranian Journal of Allergy, Asthma and Immunology, 2020
View PDFchevron_right
A single cycle influenza virus coated in H7 hemagglutinin provides heterotypic protection and neutralising antibody responses to both glycoproteins
Alain Townsend
2017
View PDFchevron_right
Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model
Wen-Chun Liu
Frontiers in Immunology, 2019
View PDFchevron_right
Administration of Multivalent Influenza Virus Recombinant Hemagglutinin Vaccine in Combination-Adjuvant Elicits Broad Reactivity Beyond the Vaccine Components
Erwin Strahsburger
Frontiers in Immunology, 2021
View PDFchevron_right
The antibody landscapes against Group 1 and 2 influenza virus hemagglutinin following AS03 and MF59 adjuvanted H5N1 vaccination
Rafael Assis
2021
View PDFchevron_right
Adjuvanted Influenza Vaccines Elicits Higher Antibody Responses against the A(H3N2) Subtype than Non-Adjuvanted Vaccines
Laura Sánchez de Prada
Vaccines
View PDFchevron_right
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial
Yuxuan Zhang
The Lancet, 2010
View PDFchevron_right
Potency, efficacy, and antigenic mapping of H7 avian influenza virus vaccines against the 2012 H7N3 highly pathogenic avian influenza virus from Mexico
D. Kapczynski
Avian diseases, 2014
View PDFchevron_right
AS03 A ‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age
emmanuel hanon
Clinical Infectious Diseases, 2010
View PDFchevron_right
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial
Disha Bhavsar
Nature Medicine
View PDFchevron_right
H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus
Svetlana Donina
Vaccine, 2013
View PDFchevron_right
Low immunogenicity predicted for emerging avian-origin H7N9: Implication for influenza vaccine design
F. Terry, M. Ardito
2013
View PDFchevron_right
AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice
Frederick Vogel
Vaccine, 2010
View PDFchevron_right
Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: A phase III, randomized trial
Aurelio Cruz-Valdez
Vaccine, 2014
View PDFchevron_right
Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial
Henderik Frijlink
BMC infectious diseases, 2017
View PDFchevron_right